This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Marco, F.
Right arrow Articles by Jones, R. N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Marco, F.
Right arrow Articles by Jones, R. N.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 1998, p. 161-163, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

In Vitro Activities of Voriconazole (UK-109,496) and Four Other Antifungal Agents against 394 Clinical Isolates of Candida spp.

F. Marco,dagger M. A. Pfaller,* S. Messer, and R. N. Jones

Department of Pathology, University of Iowa College of Medicine, Iowa City, Iowa 52242

Received 1 August 1997/Returned for modification 26 September 1997/Accepted 13 October 1997

Voriconazole (formerly UK-109,496) is a new monotriazole antifungal agent which has potent activity against Candida, Cryptococcus, and Aspergillus species. We investigated the in vitro activity of voriconazole compared to those of fluconazole, itraconazole, amphotericin B, and flucytosine (5FC) against 394 bloodstream isolates of Candida (five species) obtained from more than 30 different medical centers. MICs of all antifungal drugs were determined by the method recommended by the National Committee for Clinical Laboratory Standards using RPMI 1640 test medium. Overall, voriconazole was quite active against all the yeast isolates (MIC at which 90% of the isolates are inhibited [MIC90], <= 0.5 µg/ml). Candida albicans was the most susceptible species (MIC90, 0.06 µg/ml) and Candida glabrata and Candida krusei were the least (MIC90, 1 µg/ml). Voriconazole was more active than amphotericin B and 5FC against all species except C. glabrata and was also more active than itraconazole and fluconazole. For isolates of Candida spp. with decreased susceptibility to fluconazole and itraconazole MICs of voriconazole were also higher. Based on these results, voriconazole has promising antifungal activity and further in vitro and in vivo investigations are warranted.

* Corresponding author. Mailing address: Medical Microbiology Division, Department of Pathology, 606 GH, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 384-9566. Fax: (319) 356-4916. E-mail: mpfaller{at}blue.weeg.uiowa.edu.

dagger Present address: Microbiology Laboratory, Hospital Clinic, University of Barcelona, 08036-Barcelona, Spain.

Antimicrobial Agents and Chemotherapy, January 1998, p. 161-163, Vol. 42, No. 1
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Hsueh, P.-R., Lau, Y.-J., Chuang, Y.-C., Wan, J.-H., Huang, W.-K., Shyr, J.-M., Yan, J.-J., Yu, K.-W., Wu, J.-J., Ko, W.-C., Yang, Y.-C., Liu, Y.-C., Teng, L.-J., Liu, C.-Y., Luh, K.-T. (2005). Antifungal Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species from Taiwan: Surveillance of Multicenter Antimicrobial Resistance in Taiwan Program Data from 2003. Antimicrob. Agents Chemother. 49: 512-517 [Abstract] [Full Text]  
  • Linares, M. J., Charriel, G., Solis, F., Rodriguez, F., Ibarra, A., Casal, M. (2005). Susceptibility of Filamentous Fungi to Voriconazole Tested by Two Microdilution Methods. J. Clin. Microbiol. 43: 250-253 [Abstract] [Full Text]  
  • Serrano, M. C., Ramirez, M., Morilla, D., Valverde, A., Chavez, M., Espinel-Ingroff, A., Claro, R., Fernandez, A., Almeida, C., Martin-Mazuelos, E. (2004). A comparative study of the disc diffusion method with the broth microdilution and Etest methods for voriconazole susceptibility testing of Aspergillus spp.. J Antimicrob Chemother 53: 739-742 [Abstract] [Full Text]  
  • Linares, M. J., Charriel, G., Solis, F., Casal, M. (2004). Comparison of Two Microdilution Methods for Testing Susceptibility of Candida spp. to Voriconazole. J. Clin. Microbiol. 42: 899-902 [Abstract] [Full Text]  
  • Serrano, M. C., Morilla, D., Valverde, A., Chavez, M., Espinel-Ingroff, A., Claro, R., Ramirez, M., Mazuelos, E. M. (2003). Comparison of Etest with Modified Broth Microdilution Method for Testing Susceptibility of Aspergillus spp. to Voriconazole. J. Clin. Microbiol. 41: 5270-5272 [Abstract] [Full Text]  
  • Pearson, M. M, Rogers, P D., Cleary, J. D, Chapman, S. W (2003). Voriconazole: A New Triazole Antifungal Agent. The Annals of Pharmacotherapy 37: 420-432 [Abstract] [Full Text]  
  • Maxwell, M. J., Messer, S. A., Hollis, R. J., Diekema, D. J., Pfaller, M. A. (2003). Evaluation of Etest Method for Determining Voriconazole and Amphotericin B MICs for 162 Clinical Isolates of Cryptococcus neoformans. J. Clin. Microbiol. 41: 97-99 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Diekema, D. J. (2002). In Vitro Activities of Ravuconazole and Voriconazole Compared with Those of Four Approved Systemic Antifungal Agents against 6,970 Clinical Isolates of Candida spp.. Antimicrob. Agents Chemother. 46: 1723-1727 [Abstract] [Full Text]  
  • PELLETIER, R., LORANGER, L., MARCOTTE, H., DE CAROLIS, E. (2002). Voriconazole and fluconazole susceptibility of Candida isolates. J Med Microbiol 51: 479-483 [Abstract] [Full Text]  
  • Sugar, A. M., Liu, X.-P. (2001). Efficacy of Voriconazole in Treatment of Murine Pulmonary Blastomycosis. Antimicrob. Agents Chemother. 45: 601-604 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Houston, A., Mills, K., Bolmstrom, A., Jones, R. N. (2000). Evaluation of the Etest Method for Determining Voriconazole Susceptibilities of 312 Clinical Isolates of Candida Species by Using Three Different Agar Media. J. Clin. Microbiol. 38: 3715-3717 [Abstract] [Full Text]  
  • Manavathu, E. K., Cutright, J. L., Loebenberg, D., Chandrasekar, P. H. (2000). A comparative study of the in vitro susceptibilities of clinical and laboratory-selected resistant isolates of Aspergillus spp. to amphotericin B, itraconazole, voriconazole and posaconazole (SCH 56592). J Antimicrob Chemother 46: 229-234 [Abstract] [Full Text]  
  • Klepser, M. E., Malone, D., Lewis, R. E., Ernst, E. J., Pfaller, M. A. (2000). Evaluation of Voriconazole Pharmacodynamics Using Time-Kill Methodology. Antimicrob. Agents Chemother. 44: 1917-1920 [Abstract] [Full Text]  
  • Perea, S., Pennick, G. J., Modak, A., Fothergill, A. W., Sutton, D. A., Sheehan, D. J., Rinaldi, M. G. (2000). Comparison of High-Performance Liquid Chromatographic and Microbiological Methods for Determination of Voriconazole Levels in Plasma. Antimicrob. Agents Chemother. 44: 1209-1213 [Abstract] [Full Text]  
  • Chiou, C. C., Groll, A. H., Walsh, T. J. (2000). New Drugs and Novel Targets for Treatment of Invasive Fungal Infections in Patients with Cancer. The Oncologist 5: 120-135 [Abstract] [Full Text]  
  • Chavez, M., Bernal, S., Valverde, A., Gutierrez, M. J., Quindos, G., Mazuelos, E. M. (1999). In-vitro activity of voriconazole (UK-109,496), LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients. J Antimicrob Chemother 44: 697-700 [Abstract] [Full Text]  
  • Hoban, D. J., Zhanel, G. G., Karlowsky, J. A. (1999). In Vitro Susceptibilities of Candida and Cryptococcus neoformans Isolates from Blood Cultures of Neutropenic Patients. Antimicrob. Agents Chemother. 43: 1463-1464 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Gee, S., Joly, S., Pujol, C., Sullivan, D. J., Coleman, D. C., Soll, D. R. (1999). In Vitro Susceptibilities of Candida dubliniensis Isolates Tested against the New Triazole and Echinocandin Antifungal Agents. J. Clin. Microbiol. 37: 870-872 [Abstract] [Full Text]  
  • Pfaller, M. A., Zhang, J., Messer, S. A., Brandt, M. E., Hajjeh, R. A., Jessup, C. J., Tumberland, M., Mbidde, E. K., Ghannoum, M. A. (1999). In Vitro Activities of Voriconazole, Fluconazole, and Itraconazole against 566 Clinical Isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43: 169-171 [Abstract] [Full Text]  
  • Pfaller, M. A., Messer, S. A., Hollis, R. J., Jones, R. N., Doern, G. V., Brandt, M. E., Hajjeh, R. A. (1998). In Vitro Susceptibilities of Candida Bloodstream Isolates to the New Triazole Antifungal Agents BMS-207147, Sch 56592, and Voriconazole. Antimicrob. Agents Chemother. 42: 3242-3244 [Abstract] [Full Text]  
  • Ball, K., Sweeney, M. P., Baxter, W. P., Bagg, J. (1998). Fluconazole sensitivities of Candida species isolated from the mouths of terminally ill cancer patients. AM J HOSP PALLIAT CARE 15: 315-319 [Abstract]  
  • McGinnis, M. R., Pasarell, L. (1998). In Vitro Testing of Susceptibilities of Filamentous Ascomycetes to Voriconazole, Itraconazole, and Amphotericin B, with Consideration of Phylogenetic Implications. J. Clin. Microbiol. 36: 2353-2355 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»